Baike Biotech (688276.SH): The clinical trial application for the combined vaccine for adsorbed acellular pertussis (two components) has been approved for use in adults and adolescents.

The Wise Wealth APP News, Baiker Biology (688276.SH) announced that the company recently received the "Drug Clinical Trial Approval Notification" for the Adsorbed Uncellular Bacterial (Two-Component) and White Break Combination Vaccine (for adults and adolescents) issued by the National Medical Products Administration.